23.01
23.01 (0%)
As of Mar 08, 2024
Harpoon Therapeutics, Inc. [HARP]
Source:
Company Overview
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (650) 443-7400 |
| Industry | manufacturing |
| CEO | Julie Eastland |
| Website | www.harpoontx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $4.4 |
| Operating Profit | $-12.1 |
| Net Income | $-1.8 |
| Net Cash | $-34.3 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -272.9 |
| Profit as % of Revenues | |
| Profit as % of Assets | -3% |
| Profit as % of Stockholder Equity | -39.7% |
Management Effectiveness
| Return on Equity | -39.7% |
| Return on Assets | -3.8% |
| Turnover Ratio | 0.1% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $47.6 |
| Total Liabilities | $43 |
| Operating Cash Flow | $-51 |
| Investing Cash Flow | $-11 |
| Financing Cash Flow | $27.6 |
